Auto Sector

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

EU Fines Ranbaxy

EU Fines Ranbaxy

EU fines Ranbaxy, others for blocking cheaper drugs.  Full Article 

Asian Stocks Outlook

Asian Stocks Outlook

Asian stocks to lead the way to year's end, Fed seen pulling back - Reuters Poll.  Full Article 

Trade Reforms

Trade Reforms

U.S. groups form alliance to push for Indian trade reforms.  Full Article 

Options Before Fed

Options Before Fed

Fed seen keeping options open on pace of bond buying.  Full Article 

Financing Trouble

Financing Trouble

U.S. court lets stand Ex-Im Bank loan for Air India.  Full Article 

Advertising Milestone

Advertising Milestone

Exclusive - Facebook reaches 1 million active advertisers.  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

Novartis gets U.S. approval to buy Fougera

Stocks

   

Mon Jul 16, 2012 10:32pm IST

* Novartis must give up rights to three medicinal creams

* Fougera will be folded into Sandoz generics unit

WASHINGTON, July 16 (Reuters) - Swiss drugmaker Novartis has won U.S. antitrust approval to close its purchase of generic dermatology products maker Fougera.

The Federal Trade Commission said on Monday that as a condition of approval, Novartis agreed to give up the rights to market three topical skin care medicines made by Tolmar Inc and to cancel a deal for a fourth.

Novartis said in May that it would buy Fougera for $1.53 billion from a consortium of private equity funds led by Nordic Capital, DLJ Merchant Banking and Avista Capital Partners.

The three generic creams that Novartis must give up marketing rights to are a topical solution to treat psoriasis, a local anesthetic, and a cream to treat rosacea, which causes chronically red skin, the FTC said.

In addition to generic dermatology products, Fougera also has a branded specialty pharmaceuticals business. It had 2011 sales of $429 million.

Fougera, based in Melville, New York, will be folded into Novartis' Sandoz generics unit.

A spokeswoman for Novartis was not immediately available to comment on Monday.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.